Compared with that in tumours, the increase of IL-1β, IL-18, and HMGB1 levels in the serum was not severe, suggesting that TIOs+NIR3-triggered antitumour immune response is relatively safe and does not cause hyperactive immune response or substantial systematic inflammation (Supplementary Fig. 18b). The gene discussed is IL18; the disease is neoplasm.